GeNeuro SA Profile Avatar - Palmy Investing

GeNeuro SA

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…

Biotechnology
CH, Plan-les-Ouates [HQ]
Strategy & Leadership

Qualitative Analysis

Business

Framework: SWOT 7's
End of GNRO.PA's Analysis
CIK: - CUSIP: H33418106 ISIN: CH0308403085 LEI: - UEI: -
Secondary Listings
GNRO.PA has no secondary listings inside our databases.